Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-03-22 / Nat. Rev. Cancer 2012 Mar;12(4):252-64https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-03-22 / Nat. Rev. Cancer 2012 Mar;12(4):252-642012-03-22 00:00:002019-02-15 08:35:56The blockade of immune checkpoints in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-804https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-8042012-03-20 00:00:002019-02-15 08:48:48Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-03-15 / J. Biomed. Biotechnol. 2012;2012:425476https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-03-15 / J. Biomed. Biotechnol. 2012;2012:4254762012-03-15 00:00:002019-02-15 08:39:57Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R39https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R392012-03-07 00:00:002019-02-15 08:50:03Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-03-01 / Future Microbiol 2012 Mar;7(3):347-67https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-03-01 / Future Microbiol 2012 Mar;7(3):347-672012-03-01 00:00:002019-02-15 09:21:32Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-03-01 / Pancreas 2012 Mar;41(2):195-205https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-03-01 / Pancreas 2012 Mar;41(2):195-2052012-03-01 00:00:002019-02-15 08:52:32Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-13https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-132012-01-26 00:00:002019-02-15 08:48:05Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-01-17 / Cancer 2012 Sep;118(17):4354-62https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-01-17 / Cancer 2012 Sep;118(17):4354-622012-01-17 00:00:002023-03-07 13:04:41HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-01-10 / JOP 2012 Jan;13(1):45-53https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-01-10 / JOP 2012 Jan;13(1):45-532012-01-10 00:00:002012-01-10 00:00:00Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-24https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-242012-01-03 00:00:002019-02-15 08:46:00Immunotherapy for metastatic colorectal cancer: present status and new options
The blockade of immune checkpoints in cancer immunotherapy
Cancer immunotherapy via dendritic cells
Extracellular vesicles–vehicles that spread cancer genes
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination
Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
Virotherapy of neuroendocrine tumors
Targeting pediatric cancer stem cells with oncolytic virotherapy
Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses
Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
Immunotherapy for metastatic colorectal cancer: present status and new options
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation